IL193567A - Sterilfiridine and history of sterilfiridine radiolabeled preparations, preparations containing them, diagnostic preparations and their use - Google Patents

Sterilfiridine and history of sterilfiridine radiolabeled preparations, preparations containing them, diagnostic preparations and their use

Info

Publication number
IL193567A
IL193567A IL193567A IL19356708A IL193567A IL 193567 A IL193567 A IL 193567A IL 193567 A IL193567 A IL 193567A IL 19356708 A IL19356708 A IL 19356708A IL 193567 A IL193567 A IL 193567A
Authority
IL
Israel
Prior art keywords
alkyl
compound
hydroxy
hydrogen
halogen
Prior art date
Application number
IL193567A
Other languages
English (en)
Hebrew (he)
Other versions
IL193567A0 (en
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of IL193567A0 publication Critical patent/IL193567A0/en
Publication of IL193567A publication Critical patent/IL193567A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL193567A 2006-03-30 2008-08-20 Sterilfiridine and history of sterilfiridine radiolabeled preparations, preparations containing them, diagnostic preparations and their use IL193567A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78715606P 2006-03-30 2006-03-30
PCT/US2007/007400 WO2007126733A2 (en) 2006-03-30 2007-03-26 Styrylpyridine derivatives and their use for binding and imaging amyloid plaques

Publications (2)

Publication Number Publication Date
IL193567A0 IL193567A0 (en) 2009-05-04
IL193567A true IL193567A (en) 2014-03-31

Family

ID=38326579

Family Applications (1)

Application Number Title Priority Date Filing Date
IL193567A IL193567A (en) 2006-03-30 2008-08-20 Sterilfiridine and history of sterilfiridine radiolabeled preparations, preparations containing them, diagnostic preparations and their use

Country Status (34)

Country Link
US (3) US7687052B2 (el)
EP (3) EP1999109B1 (el)
JP (1) JP5290954B2 (el)
KR (1) KR101376807B1 (el)
CN (1) CN101522624B (el)
AT (1) ATE539060T1 (el)
AU (1) AU2007243712B2 (el)
BR (1) BRPI0710225B1 (el)
CA (1) CA2644530C (el)
CR (1) CR10329A (el)
CY (3) CY1113048T1 (el)
DK (2) DK1999109T3 (el)
EA (1) EA017898B1 (el)
EC (1) ECSP088783A (el)
ES (2) ES2628882T3 (el)
FR (1) FR13C0034I2 (el)
GT (1) GT200800201A (el)
HR (2) HRP20120135T1 (el)
HU (2) HUE032660T2 (el)
IL (1) IL193567A (el)
LT (1) LT2363392T (el)
LU (1) LU92232I2 (el)
MX (1) MX2008012527A (el)
NO (2) NO342090B1 (el)
NZ (1) NZ570887A (el)
PL (2) PL1999109T3 (el)
PT (2) PT1999109E (el)
RS (2) RS56171B1 (el)
SG (1) SG173338A1 (el)
SI (2) SI1999109T1 (el)
TW (1) TWI399366B (el)
UA (1) UA97802C2 (el)
WO (1) WO2007126733A2 (el)
ZA (1) ZA200807955B (el)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1999109B1 (en) * 2006-03-30 2011-12-28 The Trustees Of The University Of Pennsylvania Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
EP2172444A4 (en) * 2007-07-04 2010-12-22 Univ Tohoku PET SENSOR HAVING ALCOXY GROUP SUBSTITUTED BY FLUORIN ATOM AND HYDROXY GROUP
JP5603855B2 (ja) * 2008-04-04 2014-10-08 アビッド レディオファーマシューティカルズ、インク． 神経変成疾患の放射性薬剤による画像化
WO2010078370A1 (en) * 2008-12-31 2010-07-08 Avid Radiopharmaceuticals, Inc. Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof
EP2451760A1 (en) * 2009-07-10 2012-05-16 Bayer Pharma Aktiengesellschaft Usage of low to medium-pressure liquid chromatography for the purification of radiotracers
US20120263646A1 (en) 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
AU2010334929B2 (en) * 2009-12-23 2015-04-23 Life Molecular Imaging Limited Formulations suitable for pet imaging with hydrophobic pet agents
WO2011141515A1 (en) 2010-05-14 2011-11-17 Bayer Pharma Aktiengesellschaft Diagnostic agents for amyloid beta imaging
AU2011260421B2 (en) 2010-06-04 2015-06-04 Life Molecular Imaging Limited Method for production of F-18 labeled amyloid beta ligands
TWI504414B (zh) 2010-06-04 2015-10-21 Bayer Schering Pharma Ag 生產Ｆ－１８標記之Ａβ配位體之方法
MX2012014116A (es) * 2010-06-04 2013-08-08 Piramal Imaging Sa Metodo para la produccion de ligandos beta amiloide marcados con 18f.
EA025823B1 (ru) * 2010-06-04 2017-02-28 Пирамаль Имэджинг Са Способ получения f-18 меченых лигандов бета-амилоида
CN101891674B (zh) * 2010-06-24 2012-11-14 山东大学 4-苯乙烯基吡啶类化合物及其制备方法与应用
US9259495B2 (en) * 2010-10-12 2016-02-16 Mayo Foundation For Medical Education And Research Imaging of meningiomas using phenylbenzothiazole, stilbene, or biphenylalkyne derivatives
US20140079635A1 (en) * 2011-03-30 2014-03-20 Case Western Reserve University Molecular probes for detecting lipid composition
WO2012145169A2 (en) 2011-04-21 2012-10-26 The Regents Of The University Of California Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles
EP2768790A1 (en) 2011-10-19 2014-08-27 Piramal Imaging SA IMPROVED METHOD FOR PRODUCTION OF F-18 LABELED Aß LIGANDS
CN104244991A (zh) 2012-04-10 2014-12-24 蓝瑟斯医学影像公司 放射性药物合成方法
JP6099045B2 (ja) * 2013-04-30 2017-03-22 国立大学法人京都大学 トリアゾロピリミジン誘導体化合物
JP2014218454A (ja) * 2013-05-07 2014-11-20 日本メジフィジックス株式会社 スチリルピリジン誘導体化合物
JP6041751B2 (ja) * 2013-05-07 2016-12-14 日本メジフィジックス株式会社 スチリルピリジン誘導体化合物
CN103645254B (zh) * 2013-11-28 2015-01-07 江苏省原子医学研究所 一种Aβ斑块显像剂前体AV45的含量分析方法
SG11201609281UA (en) * 2014-05-13 2016-12-29 Hoffmann La Roche Deuterated heterocyclic compounds and their use as imaging agents
AU2016308189B2 (en) * 2015-08-18 2021-03-11 The Regents Of The University Of California Nitroxide containing amyloid binding agents for imaging and therapeutic uses
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
CN109400615B (zh) * 2017-08-18 2021-07-16 上海交通大学医学院附属新华医院 一种靶向β-淀粉样蛋白的香豆素类化合物及其制备与应用
CN108299287A (zh) * 2018-01-02 2018-07-20 北京师范大学 与Aβ斑块具有高亲和力的N2S2类吡啶基苯乙烯化合物
CN114805190A (zh) * 2022-06-08 2022-07-29 吉林大学第一医院 一种甲基苯胺类Aβ蛋白显像剂的双柱合成方法
WO2024107620A1 (en) 2022-11-14 2024-05-23 Eli Lilly And Company Polymorphic forms of florbetapir precursor av-105

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000963A1 (en) * 1990-07-12 1992-01-23 Yoshitomi Pharmaceutical Industries, Ltd. Styryl compounds and use thereof as medicine
JPH0545875A (ja) * 1991-08-08 1993-02-26 Konica Corp 感光性組成物
US6020436A (en) * 1993-03-09 2000-02-01 The Chromaline Corporation Photosensitive resin composition
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
WO2001070667A1 (fr) * 2000-03-22 2001-09-27 Bf Research Institute, Inc. Sonde de diagnostic par image, a base d'azobenzene substitue ou d'un analogue de celui-ci, pour les maladies imputables a l'accumulation d'amyloide et composition pour le diagnostic par image le contenant
US8007954B2 (en) 2000-11-09 2011-08-30 The Trustees Of The University Of Pennsylvania Use of sulfur-containing fuels for direct oxidation fuel cells
JP2002182254A (ja) 2000-12-18 2002-06-26 Fuji Photo Film Co Ltd 非線形光学材料とその製造方法
US7250525B2 (en) * 2001-08-27 2007-07-31 The Trustees Of The University Of Pennsylvania Stilbene derivatives and their use for binding and imaging amyloid plaques
CA2488273A1 (en) 2002-06-06 2003-12-18 The Trustees Of The University Of Pennsylvania Ceramic anodes and method of producing the same
AU2003258612A1 (en) * 2002-08-14 2004-03-03 4Sc Ag Pyrimidones as antiviral agents
JP4482352B2 (ja) 2004-03-11 2010-06-16 本田技研工業株式会社 固体高分子型燃料電池
WO2006078384A2 (en) * 2004-12-17 2006-07-27 The Trustees Of The University Of Pennsylvania Stilbene derivatives and their use
SG194363A1 (en) * 2004-12-17 2013-11-29 Univ Pennsylvania Stilbene derivatives and their use for binding and imaging amyloid plaques
CA2617319A1 (en) 2005-06-24 2007-01-04 The Trustees Of The University Of Pennsylvania Radiolabeled-pegylation of ligands for use as imaging agents
EP1999109B1 (en) 2006-03-30 2011-12-28 The Trustees Of The University Of Pennsylvania Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
US20080253967A1 (en) * 2007-04-13 2008-10-16 Kung Hank F Halo-Stilbene Derivatives And Their Use For Binding And Imaging Of Amyloid Plaques

Also Published As

Publication number Publication date
CY2013024I1 (el) 2015-11-04
RS56171B1 (sr) 2017-11-30
LT2363392T (lt) 2017-07-25
EP2363392B1 (en) 2017-05-03
EA200870389A1 (ru) 2009-04-28
UA97802C2 (uk) 2012-03-26
IL193567A0 (en) 2009-05-04
CN101522624A (zh) 2009-09-02
FR13C0034I2 (fr) 2014-03-07
SI1999109T1 (sl) 2012-04-30
CA2644530A1 (en) 2007-11-08
KR101376807B1 (ko) 2014-03-20
ZA200807955B (en) 2012-11-28
HRP20170857T1 (hr) 2017-12-01
ECSP088783A (es) 2008-10-31
US8840866B2 (en) 2014-09-23
HRP20120135T1 (hr) 2012-03-31
RS52222B (en) 2012-10-31
NO342090B1 (no) 2018-03-19
AU2007243712B2 (en) 2013-01-10
WO2007126733A2 (en) 2007-11-08
US20090123369A1 (en) 2009-05-14
US8506929B2 (en) 2013-08-13
SI2363392T1 (sl) 2017-09-29
CA2644530C (en) 2015-05-19
EP1999109B1 (en) 2011-12-28
US7687052B2 (en) 2010-03-30
NZ570887A (en) 2011-05-27
CR10329A (es) 2008-10-29
FR13C0034I1 (el) 2013-08-09
CN101522624B (zh) 2013-11-06
US20080038195A1 (en) 2008-02-14
US20130129624A1 (en) 2013-05-23
CY1119048T1 (el) 2018-01-10
TWI399366B (zh) 2013-06-21
LU92232I2 (fr) 2013-08-26
BRPI0710225B1 (pt) 2021-07-13
CY2013024I2 (el) 2015-11-04
DK2363392T3 (en) 2017-07-03
LU92232I9 (el) 2019-01-15
WO2007126733A3 (en) 2008-03-06
AU2007243712A1 (en) 2007-11-08
BRPI0710225A2 (pt) 2011-08-02
KR20080106564A (ko) 2008-12-08
GT200800201A (es) 2009-08-20
JP5290954B2 (ja) 2013-09-18
EP2363391A1 (en) 2011-09-07
MX2008012527A (es) 2008-10-14
ATE539060T1 (de) 2012-01-15
HUS1300028I1 (hu) 2017-08-28
DK1999109T3 (da) 2012-04-02
HUE032660T2 (en) 2017-10-30
JP2009532349A (ja) 2009-09-10
ES2628882T3 (es) 2017-08-04
EA017898B1 (ru) 2013-04-30
EP2363392A1 (en) 2011-09-07
CY1113048T1 (el) 2015-11-04
EP1999109A2 (en) 2008-12-10
SG173338A1 (en) 2011-08-29
NO2018030I1 (no) 2018-09-11
TW200838852A (en) 2008-10-01
PL2363392T3 (pl) 2017-10-31
NO20084590L (no) 2008-12-29
PT1999109E (pt) 2012-03-16
PL1999109T3 (pl) 2012-05-31
PT2363392T (pt) 2017-06-15
ES2378785T3 (es) 2012-04-17

Similar Documents

Publication Publication Date Title
CA2644530C (en) Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
AU2008203856B2 (en) Stilbene derivatives and their use for binding and imaging amyloid plaques
AU2002323417A1 (en) Stilbene derivatives and their use for binding and imaging amyloid plaques
US20110158907A1 (en) Diphenyl-heteroaryl derivatives and their use for binding and imaging amyloid plaques
EP1838298A2 (en) Stilbene derivatives and their use for binding and imaging amyloid plaques
WO2006078384A2 (en) Stilbene derivatives and their use
CA2672187A1 (en) Acetylene derivatives and their use for binding and imaging amyloid plaques

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed